---
title: "NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting | NPCE Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288064810.md"
description: "NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting | NPCE Stock News"
datetime: "2026-05-29T04:05:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288064810.md)
  - [en](https://longbridge.com/en/news/288064810.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288064810.md)
generator: "portal-rs"
---

# NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting | NPCE Stock News

NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting | NPCE Stock News

### Related Stocks

- [NPCE.US](https://longbridge.com/en/quote/NPCE.US.md)

## Related News & Research

- [NeuroPace to Participate in 2026 Cantor Global Healthcare Conference | NPCE Stock News](https://longbridge.com/en/news/297699650.md)
- [NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages](https://longbridge.com/en/news/297397212.md)
- [NPCE: Q2 2026 RNS revenue grew 21% year-over-year, with robust outlook and expanding market reach](https://longbridge.com/en/news/295587869.md)
- [NeuroPace Q2 revenue slightly beats estimates](https://longbridge.com/en/news/295575733.md)
- [NeuroPace says FDA deems epilepsy label expansion filing not approvable in current form](https://longbridge.com/en/news/294110473.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**